ReviewF1000Research2016
Recent advances in T-cell engineering for use in immunotherapy.
Review in F1000Research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 19 citations in OpenAlex.
- Article
- Six events that shaped antibody approvals in oncology.Frontiers in immunology · 2025Review
- Cancer therapy with antibodies.Nature reviews. Cancer · 2024Review
- Conformational plasticity of RAS Q61 family of neoepitopes results in distinct features for targeted recognition.Nature communications · 2023Article
- Bispecific antibodies targeting mutantScience immunology · 2021Article
- A Universal CAR-NK Cell Targeting Various Epitopes of HIV-1 gp160.ACS chemical biology · 2020Article
- Structure-guided engineering of the affinity and specificity of CARs against Tn-glycopeptides.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- T Cell Reprogramming Against Cancer.Methods in molecular biology (Clifton, N.J.) · 2020Review
- Targeting mutant p53-expressing tumours with a T cell receptor-like antibody specific for a wild-type antigen.Nature communications · 2019Article
- T Cell Receptors for Gene Transfer in Adoptive T Cell Therapy.Critical reviews in immunology · 2019Review
- Identifying neoantigens for use in immunotherapy.Mammalian genome : official journal of the International Mammalian Genome Society · 2018Review
- B-cell populations are expanded in breast cancer patients compared with healthy controls.Breast cancer (Tokyo, Japan) · 2018Article
- IL-2 and Beyond in Cancer Immunotherapy.Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research · 2018Review
- Soluble T-cell receptor design influences functional yield in an E. coli chaperone-assisted expression system.PloS one · 2018Article
- Interpreting T-Cell Cross-reactivity through Structure: Implications for TCR-Based Cancer Immunotherapy.Frontiers in immunology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Adoptive T-cell therapies have shown exceptional promise in the treatment of cancer, especially B-cell malignancies. Two distinct strategies have been used to redirect the activity of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.